NEWS CENTER

PRESS RELEASES

11.19.2020
Epic Sciences Enters into Exclusive Licensing Agreement and Collaboration with USC Michelson Center to Advance Next-Generation Liquid Biopsy Technology for Precision Oncology
Epic Sciences, Inc. today announced it has entered into an exclusive license and collaboration agreement with Dr. Peter Kuhn and the USC Michelson Center for Convergent Bioscience. Dr. Kuhn is a founding member of the USC Michelson Center and leads USC’s Convergent Science Institute in Cancer (CSI-Cancer). The collaboration will improve Epic’s platform and enable more precise characterization of rare circulating tumor cells (CTCs), which Epic is developing into liquid-biopsy diagnostics used for characterizing a patient’s cancer to guide treatment decisions. Read Full Release
10.29.2020
Epic Sciences and Predicine Jointly Announce Strategic Partnership to Expand Liquid Biopsy Offerings to Biopharmaceutical Partners
Epic Sciences, Inc. and Predicine, Inc. today announced they have entered into a global strategic partnership to offer biopharmaceutical companies access to both Predicine’s ctDNA-based testing and Epic’s CTC-based testing. Predicine’s lead offering is PredicineATLASÔ, the broadest CLIA-certified ctDNA-based assay that analyzes 600 cancer-related genes, using next generation sequencing. Epic’s CTC-based platform offers testing of AR-V7, AR-N term, PSMA, ER, PR and other phenotypic tests. The combination of both approaches allows pharmaceutical partners engaged in clinical trials to measure both genotypic and phenotypic markers from a single blood draw. Read Full Release
09.14.2020
Epic Sciences Enters into Collaboration with Q2 Solutions to Expand Liquid Biopsy Capabilities
Epic Sciences, Inc. today announced it has entered into a global collaboration with Q2 Solutions®, a leading clinical trial laboratory services organization,to offer Illumina®’s TruSight Oncology 500 liquid biopsy test to Epic’s global biopharmaceutical customers. The addition of TruSight Oncology 500 to Epic’s portfolio of testing capabilities, brings ctDNA analysis to Epic’s CTC-based platform that enumerates and characterizes circulating tumor cells (CTCs). TruSight Oncology 500 enables analysis of circulating tumor DNA (ctDNA) of the full exonic sequence of over 500 genes in key cancer-related pathways, and includes identifying single-nucleotide variants, indels, copy number variants, DNA fusions, microsatellite instability (MSI) and tumor mutational burden (TMB). Read Full Release
05.30.2020
Epic Sciences to Present Multiple Abstracts at ASCO 2020 Highlighting the Importance of CTCs in Liquid Biopsy
Epic Sciences, Inc. today announced that it will present three abstracts at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program to be held from May 29 – June 2, 2020. Epic Sciences will present new data demonstrating the role of circulating tumor cells (CTCs) in cancer prognosis and treatment outcomes. Read Full Release

NEWS

11.19.2020 | 360Dx
Epic Sciences, USC Michelson Center Sign Licensing Agreement for NGS Liquid Biopsy Research
NEW YORK – Epic Sciences said on Thursday that it has signed a licensing agreement with the University of Southern California's Michelson Center for Convergent Bioscience to improve the firm's liquid biopsy platform and allow for more precise characterization of rare circulating tumor cells (CTCs). Read Full Article
11.09.2020 | Clinical OMICs
Companies are rapidly advancing liquid biopsies as the go-to technology for cancer treatment monitoring and recurrence
Liquid biopsies are becoming increasingly sensitive and personal thanks to advances in next-generation sequencing and target amplification. In addition, machine learning algorithms are being used on large datasets to characterize the molecular signatures of various cancer types. Read Full Article
05.28.2020 | Clinical OMICs
Comprehensive Approach - Epic Sciences has retooled its management team and is combining CTC and ctDNA technologies in its pursuit of comprehensive cancer profiling
In the realm of liquid biopsy as a tool for precision medicine and the different cells and fractions that can be collected from a standard blood draw, there has always been a sense that there is something missing. Circulating tumor cells (CTCs,) hard to collect, and even harder to collect as a viable cell, would never be the source of all the information needed to make a targeted cancer diagnosis. Read Full Article
02.25.2020 | OncLive
Dr. Armstrong on the Rationale of the PROPHECY Trial in mCRPC
Andrew J. Armstrong, MD, professor of medicine, associate professor in pharmacology and cancer biology, and professor in surgery at Duke University School of Medicine and a member of the Duke Cancer Institute, discusses the rationale of the PROPHECY trial in metastatic castration-resistant prostate cancer (mCRPC). Read Full Article

EVENTS

ISLB 2020
The Epic Sciences team presented at the virtual ISLB 2020 Annual Congress Meeting - October 30, 2020. More Info
ASCO 2020
The Epic Sciences team will be presenting at the virtual ASCO 2020 Annual Meeting - From May 29 - 31, 2020. More Info
SABCS 2019
The Epic Sciences team will be attending and exhibiting at the San Antonio Breast Cancer Symposium - Booth #626 - in San Antonio, TX from December 10 - December 14, 2019. More Info
ASCO 2019
The Epic Sciences team will be attending ASCO 2019 Annual Meeting - Booth #2066 - in Chicago, IL from May 31 - June 4, 2019. More Info